tetM-carrying N. gonorrhoeae prevalence in US surveillance reaches ≥30% by EOY 2026 OR ≥3 independent confirmed extensively drug-resistant (ceftriaxone+azithromycin+ciprofloxacin simultaneously resistant) N. gonorrhoeae transmission clusters documented in US/EU/AU during 2026, threatening the doxyPEP era and last-line cephalosporin therapy.

ECDC will formally classify Candidozyma auris (formerly Candida auris) as endemic in ≥3 EU/EEA countries via a technical report, surveillance update, or risk assessment by 2026-10-17, formalizing the trajectory described in Medscape 2026-04-13 ("C auris Is Now Endemic in Europe. Can It Be Contained?") and CIDRAP 2025-09-11 ("Multidrug-resistant yeast cases rising rapidly in Europe, survey shows").

CDC will publish a Morbidity and Mortality Weekly Report (MMWR) early release or health advisory specifically characterizing XDR Shigella (azithromycin + fluoroquinolone + 3GC resistant) geographic spread and treatment guidance within 60 days of the April 13 2026 emergence report (by June 12 2026), consistent with CDC's precedent of issuing MMWR early releases for novel drug-resistant Shigella phenotypes (2022-2023 ceftriaxone-resistant Shigella MMWR).

BA.3.2 ("Cicada") will cause a detectable wastewater elevation (≥20% increase from Q1 2026 baseline) in ≥3 of the 14 monitored countries by 2026-06-30, driven by immune escape from prior SARS-CoV-2 immunity.

At least one additional distinct pediatric HIV cluster (≥10 seroconversions, children <15, different facility than Larkana/Ratodero 2019 and the Apr 2026 Punjab hospital) will be publicly reported in Pakistan within 90 days, attributed to unsafe-injection or blood-product iatrogenic transmission.